NOV 09, 2017 7:30 AM PST

Keynote Presentation: Integration of the Simplexa C. difficile Direct assay into a two-step algorithm for the laboratory diagnosis of C. difficile

Speaker
  • Professor of Pathology and Laboratory Medicine, University of Louisville│Medical Director of the Clinical Microbiology and Molecular Diagnostics Laboratory, University of Louisville Hospital
    Biography
      Dr. Snyder is the Director of Microbiology and Infectious Disease Molecular Diagnostic Laboratory at the University of Louisville Hospital. He holds the academic rank of Professor of Pathology and Laboratory Medicine in the Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine. He holds numerous memberships in professional societies including the American Society for Microbiology (ASM), Pan American Society for Clinical Virology, Infectious Disease Society of American (IDSA), and the South Central Association for Clinical Microbiology (SCACM). In addition to his daily duties, Dr. Snyder maintains an active research program focusing on clinical trials and technology/product performance assessment in addition to teaching pathology residents, infectious disease fellows, and medical students.

    Abstract

    Clostridium difficile infection (CDI) has become the leading cause of healthcare associated infections in the United States and currently accounts for 15% to 20% of infectious diarrhea in the healthcare setting.  Accurate diagnosis of CDI is criticalin promoting effective management of patients and implementing appropriate infection control measures to disrupt and prevent transmission.  Reliable diagnostic tests are needed to confirm or negative a presumptive clinical diagnosis of CDI.  Nucleic acid amplification tests (NAAT) have become available within the last ten years and have been used in one of two ways: 1) Direct testing, 2) algorithmic testing as a supplement to enzyme immunoassay (EIA) for the detection of glutamate dehydrogenase and Toxin A/B.  Much controversy exists as to which approach, direct NAAT or algorimthic is optimal for the laboratory diagnosis of CDI.  The latest NAAT-based test to enter the market is the Simplexa C. diffcile Direct Assay,   An evaluation of this technology was conducted for the purpose of determining its overall performance and potential integration into two-step algorithm testing format.  The assay was evaluated and compared to two other NAAT platforms.  The results of this evaluation are the subject of this presentation.


    Show Resources
    NOV 09, 2017 7:30 AM PST

    Keynote Presentation: Integration of the Simplexa C. difficile Direct assay into a two-step algorithm for the laboratory diagnosis of C. difficile


    Specialty

    Laboratory Testing

    Infectious Disease

    Biotechnology

    Microbiology

    Clinical Diagnostics

    Molecular Diagnostics

    Diagnostics

    Geography

    North America100%

    Registration Source

    Website Visitors100%

    Job Title

    Executive50%

    Medical Laboratory Technician50%

    Organization

    Hospital50%

    Biotech Company50%


    Show Resources
    Show Resources
    Attendees
    • See more